Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                MCM Legal, Regulatory and Policy Framework

MCM Legal, Regulatory and Policy Framework

                        Emergency Use Authorization
          Expiration Dating Extension
          MCM Emergency Use Authorities
          MCM-Related Counterterrorism Legislation
          MCM-Related Legal and Policy Presentations, Publications and Q&As
          State, Tribal, Local, and Territorial Public Health Preparedness
          Guidance and Other Information of Special Interest to MCM Stakeholders
          MCM-Related Cooperative Arrangements
          Availability of Regulatory Management Plans
          Vaccine EUA Questions and Answers for Stakeholders
          FAQs: What happens to EUAs when a public health emergency ends? Home
          Emergency Preparedness and Response
          Counterterrorism and Emerging Threats
          Medical Countermeasures Initiative (MCMi)
          MCM Legal, Regulatory and Policy Framework
          MCM-Related Cooperative ArrangementsMCM Legal, Regulatory and Policy Framework MCM-Related Cooperative Arrangements
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              Ball representing EarthFDA and the Medical Countermeasures Initiative use a variety of cooperative arrangements to further development and availability of medical countermeasures (MCMs). These include Memoranda of Understanding and Confidentiality Commitments. Current arrangements are listed below by category, then by effective date, with the newest first in each list.

Memoranda of Understanding (MOUs)

FDA and the Veterans Health Administration (VHA) [MOU 225-23-008]
	May 10, 2023: To provide a framework for collaboration to facilitate the development of requirements for trusted networks needed to help enable the use of distributed manufacturing and digital stockpiles to protect public health by promoting supply chain resilience during emergencies, shortages, and pandemics.
	FDA, the CDC National Institute for Occupational Safety and Health (NIOSH), and the Occupational and Safety Health Administration (OSHA) [MOU 225-22-026]
	April 12, 2023: To provide a framework for continued collaboration, including the sharing of certain information to facilitate coordination, decision-making, law enforcement activities, and guidance or regulation development through the agencies’ respective authorities and overlapping missions.
	FDA and the National Center for Advancing Translational Sciences (NCATS) at NIH [MOU 225-23-003]
	January 12, 2023: To provide a framework between NCATS and FDA for coordination and collaborative efforts towards widespread use of microphysiological systems (MPS) in advancing novel therapies that are safe and effective, and in biomedical research for understanding pathophysiology and modeling of human diseases/conditions.
	FDA, the Centers for Disease Control and Prevention (CDC), and several stakeholders [MOU 225-22-020] 
	May 6, 2022: To collaborate on enhancing laboratory testing surge capacity outside of CDC and public health laboratories before and during public health emergencies. Partnerships and engagement between the public and private sector are crucial to supporting a significant increase in demand for diagnostic testing during a public health emergency and to respond to emerging public health threats before reaching the level of a pandemic.
	FDA, the National Institutes of Health (NIH), and the Animal and Plant Health Inspection Service (APHIS), U.S. Department of Agriculture (USDA) [MOU 225-16-010]
	June 24, 2021: MOU renewal, to set forth a framework for reciprocal cooperation which will assist each agency in meeting its responsibilities in promoting proper laboratory animal care and welfare. The original MOU was signed in 2016.
	FDA and the National Institute of Standards and Technology (NIST) [MOU 225-21-006]
	January 15, 2021: To collaborate to increase U.S. medical supply chain resilience and advance domestic manufacturing of pharmaceuticals, biopharmaceuticals, and medical devices through adoption of 21st century manufacturing technologies including smart technologies, emerging manufacturing processes, and artificial intelligence and machine learning.
	FDA, US Army Medical Research and Materiel Command [MOU 225-20-010]
	April 17, 2020: To establish a training program in the form of an inter-agency detail to support their shared interests in the training of scientific and medical personnel in medical product development and FDA’s regulatory processes.
	FDA, National Institutes of Health (NIH) , and Veterans Health Administration (VA) [MOU 225-20-008]
	March 27, 2020: To share data, and coordinate on open-source medical products for the COVID-19 response with other stakeholders such as America Makes.
	FDA and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) [MOU 225-19-013]
	April 10, 2019: MOU renewal, to provide a framework for coordination and collaborative efforts related to the development and availability of MCMs in public health medical emergencies. The original MOU was signed in 2012.
	FDA and the Department of Defense (DoD) [MOU 225-19-001]
	November 2, 2018: To establish the framework under which DoD and FDA will implement the 2017 law for enhanced engagements to facilitate the development and availability of safe and effective medical products that serve the military’s needs.
	FDA and the National Aeronautics And Space Administration (NASA) [MOU 225-18-027]
	September 26, 2018: To provide mutual support to biomedical research on drugs, biologics, and medical devices and for medical countermeasure development.
	FDA and the CDC National Institute for Occupational Safety and Health (NIOSH) [MOU 225-18-006]
	November 29, 2017: Provides a framework for coordination and collaboration between the agencies relating to regulation of surgical N95 respirators and N95 filtering facepiece respirators (FFRs) used in healthcare settings.
	FDA and the Bill and Melinda Gates Foundation[MOU 225-17-019]
	June 27, 2017: Establishes a framework to facilitate collaboration to carry out common goals to improve public health by stimulating and fostering medical product innovation and enabling medical product development, including medical countermeasures.
	FDA and the Defense Advanced Research Projects Agency (DARPA) [MOU 225-17-015]
	June 1, 2017: Promotes collaboration between FDA and DARPA, and provides a mechanism for the sharing of certain nonpublic information. (Replaces MOU 225-12-0037 [2012])
	FDA and the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Office of the Secretary for Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA), HHS [MOU 225-16-018]
	May 19, 2016: For development of innovative technologies to identify antimicrobial-resistant bacteria.
	FDA and the Centers for Disease Control and Prevention (CDC) [MOU 225-16-008]
	February 19, 2016: Establishes a framework for the agencies’ coordination in support of CDC’s use of its delegated authority to develop and issue emergency use instructions (EUI) for eligible medical countermeasures.
	FDA and the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) [MOU 225-13-028]
	March 11, 2014: Establishes a framework to promote efficiency and collaboration between FDA and PHEMCE partners to meet needs for issues related to safety, efficacy and use of drugs, biologics and medical devices for use in emergencies.International Confidentiality Commitments - Current and Potential Public Health Emergencies

FDA and the European Medicines Agency and DG SANTE (from FDA)
	August 23, 2017: New commitment allows FDA and European Commission/EMA to share full inspection reports as part of cooperative law enforcement or cooperative regulatory activities.
	FDA and the European Medicines Agency and DG SANTE (from EMA and DG SANTE)
	August 23, 2017: New commitment allows FDA and European Commission/EMA to share full inspection reports as part of cooperative law enforcement or cooperative regulatory activities.
	FDA and the World Health Organization Department of Essential Medicines and Health Products (WHO EMP)
	August 25, 2014: To help facilitate communications regarding an actual or potential public health (PH) crisis or PH emergency of international concern; allows sharing of information that is non-public but important to address public health emergencies.International Confidentiality Commitments - 2014-2015 Ebola Epidemic in West Africa

FDA and the Ministry of Public Health and Hygiene of Guinea
	September 1, 2015: To help facilitate communications between the two agencies on medical products used, or proposed to be used, for Ebola-related purposes as part of cooperative regulatory activities.
	FDA and the Pharmacy Board of Sierra Leone (PBSL)
	March 18, 2015: To help facilitate communications between FDA and the PBSL on medical products used, or proposed to be used, for Ebola-related purposes as part of cooperative regulatory activities.
	FDA and the Liberian Medicines and Health Products Regulatory Authority (LMHRA)
	February 3, 2015: To help facilitate communications between FDA and the LMHRA on medical products used, or proposed to be used, for Ebola-related purposes as part of cooperative regulatory activities.Other International Arrangements - 2014-2015 Ebola Epidemic in West Africa

International Coalition of Medicines Regulatory Authorities (ICMRA) - Statement [ARCHIVED]
	September 4, 2014: Medicines regulators to work together internationally to find innovative solutions to facilitate evaluation of and access to potential new medicines to counter Ebola outbreaks.International Confidentiality Commitments - Middle East Respiratory Syndrome Coronavirus

FDA and the Saudi Food and Drug Authority (SFDA)
	October 20, 2015: To help facilitate communications between the two agencies on medical products used, or proposed to be used, for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) as part of cooperative regulatory activities.Joint Statement of Continued Cooperation Between FDA and ANVISA, Zika Virus Disease

FDA and the Brazilian Health Regulatory Agency (ANVISA) [ARCHIVED]
	April 11, 2016: Statement of Continued Cooperation Between FDA and ANVISA - Zika Virus DiseaseRelated Links

MCMi Collaborations
	More FDA Memoranda of Understanding (MOUs)
	More FDA Confidentiality Commitments
	About FDA's International Arrangements

                                                                                  Content current as of:
      05/22/2023
              
              
Topic(s)
			  Partnerships
				    				       				    				       Emergency Response
				       				    				       Emergencies
				       				    				       ResearchHealth Topic(s)
			  Infectious Disease Treatment
			    			       			    			       Coronavirus
			       			    			       Flu
			       			    			       ZikaMCM Legal, Regulatory and Policy Framework

          
                        Emergency Use Authorization
          Expiration Dating Extension
          MCM Emergency Use Authorities
          MCM-Related Counterterrorism Legislation
          MCM-Related Legal and Policy Presentations, Publications and Q&As
          State, Tribal, Local, and Territorial Public Health Preparedness
          Guidance and Other Information of Special Interest to MCM Stakeholders
          MCM-Related Cooperative Arrangements
          Availability of Regulatory Management Plans
          Vaccine EUA Questions and Answers for Stakeholders
          FAQs: What happens to EUAs when a public health emergency ends?
 Subscribe
                        Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop